506 related articles for article (PubMed ID: 16186359)
1. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
3. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.
Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
5. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
6. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis.
Yoshimura T; Sonoda KH; Miyazaki Y; Iwakura Y; Ishibashi T; Yoshimura A; Yoshida H
Int Immunol; 2008 Feb; 20(2):209-14. PubMed ID: 18156624
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.
Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611
[TBL] [Abstract][Full Text] [Related]
8. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
9. Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.
Kohno H; Sakai T; Tsuneoka H; Imanishi K; Saito S
Exp Eye Res; 2009 Oct; 89(4):486-93. PubMed ID: 19523946
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis.
Suzuki J; Sakai J; Okada AA; Takada E; Usui M; Mizuguchi J
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):314-21. PubMed ID: 11981647
[TBL] [Abstract][Full Text] [Related]
11. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2898-905. PubMed ID: 10549650
[TBL] [Abstract][Full Text] [Related]
12. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.
Guyver CJ; Copland DA; Calder CJ; Sette A; Sidney J; Dick AD; Nicholson LB
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2027-35. PubMed ID: 16639012
[TBL] [Abstract][Full Text] [Related]
13. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
[TBL] [Abstract][Full Text] [Related]
14. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12.
Yokoi H; Kato K; Kezuka T; Sakai J; Usui M; Yagita H; Okumura K
Eur J Immunol; 1997 Mar; 27(3):641-6. PubMed ID: 9079803
[TBL] [Abstract][Full Text] [Related]
15. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
16. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis.
Xu H; Rizzo LV; Silver PB; Caspi RR
Cell Immunol; 1997 May; 178(1):69-78. PubMed ID: 9184700
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
Iwata D; Kitaichi N; Miyazaki A; Iwabuchi K; Yoshida K; Namba K; Ozaki M; Ohno S; Umezawa K; Yamashita K; Todo S; Ishida S; Onoé K
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2077-84. PubMed ID: 19907030
[TBL] [Abstract][Full Text] [Related]
18. Effects of experimental ocular inflammation on ocular immune privilege.
Ohta K; Wiggert B; Taylor AW; Streilein JW
Invest Ophthalmol Vis Sci; 1999 Aug; 40(9):2010-8. PubMed ID: 10440255
[TBL] [Abstract][Full Text] [Related]
19. Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice.
Usui Y; Takeuchi M; Hattori T; Okunuki Y; Nagasawa K; Kezuka T; Okumura K; Yagita H; Akiba H; Goto H
Arch Ophthalmol; 2009 Apr; 127(4):514-9. PubMed ID: 19365033
[TBL] [Abstract][Full Text] [Related]
20. Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNA.
Iwata D; Kitamura M; Kitaichi N; Saito Y; Kon S; Namba K; Morimoto J; Ebihara A; Kitamei H; Yoshida K; Ishida S; Ohno S; Uede T; Onoé K; Iwabuchi K
Exp Eye Res; 2010 Jan; 90(1):41-8. PubMed ID: 19766630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
